When the VCs' Customers Get Worried
This article was originally published in Start Up
Venture capital returns are down and investors in VC firms are getting itchy. To lower investment risk and cost, they're imposing new requirements: smaller funds, clawbacks with sharper claws, harsher key-man provisions, and mark-to-market valuation metrics.
You may also be interested in...
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.
Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?
Biomarkers are being used now across the whole pharmaceutical value chain, but it's unlikely we'll see a surge in the number of VC-backed biomarker discovery start-ups until the business models are proven.